Healthcare [ 7/13 ] | Biotechnology [ 61/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 8, 23 | -0.27 Increased by +43.75% | -0.23 Decreased by -17.39% |
| Aug 9, 23 | -0.32 Increased by +37.25% | -0.29 Decreased by -10.34% |
| May 4, 23 | -0.37 Increased by +22.92% | -0.35 Decreased by -5.71% |
| Mar 22, 23 | -0.46 Decreased by -21.05% | -0.45 Decreased by -2.22% |
| Nov 8, 22 | -0.48 Decreased by -17.07% | -0.47 Decreased by -2.13% |
| Aug 9, 22 | -0.51 Increased by +7.27% | -0.47 Decreased by -8.51% |
| May 12, 22 | -0.48 Increased by +30.43% | -0.47 Decreased by -2.13% |
| Mar 10, 22 | -0.38 Increased by +60.42% | -0.48 Increased by +20.83% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -14.42 M Increased by +37% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -16.9 M Increased by +30.61% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -18.34 M Increased by +20.33% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -21.63 M Increased by +64.11% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by -100% | -22.89 M Decreased by -21.73% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -24.35 M Decreased by -3.2% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -23.02 M Increased by +15.37% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by -100% | -60.26 M Decreased by -52.87% | Decreased by N/A% Decreased by N/A% |
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases in the United States. It develops ABI-5366 and ABI-1179, which is in Phase 1a/1b clinical trial to treat recurrent genital herpes; and ABI-6250, an oral hepatitis delta virus entry inhibitor that is in Phase 1a clinical studies. The company also offers ABI-4334, a next-generation capsid assembly modulator which is in Phase 1b clinical trials, for the treatment of hepatitis B virus. In addition, it provides an oral non-nucleoside polymerase inhibitor indicated to treat transplant-associated herpesviruses; and small molecule interferon-a receptor to treat hepatitis B and delta virus. Assembly Biosciences, Inc. has a collaboration agreement with Gilead Sciences, Inc. that licenses its HPI program and its NNPI program. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.